Research Studies
Back to Results
Impact of Fever Prevention in Brain Injured Patients (INTREPID)
Description
Patients randomized to the fever prevention group will have ArcticGel Pads placed on their body. These will be connected to the Arctic Sun System. The system will be programmed to keep the patient's body temperature at 98.6. Treatment will last for 14 days or until ready to be discharged from the ICU. Standard of care patients will receive standard medical care as prescribed by the medical team.
MoreDetails
Age
Adult
Eligibility
Adult, primary diagnosis of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage
Phase
Not Applicable - Describes studies without FDA-defined phases, including studies of devices or behavioral interventions.
Type of Study
Treatment
Location
University of Colorado Hospital
Principal Investigator
Luis Cava Prado, MD
Study ID
Protocol Number: 18-0548
ClinicalTrials.gov: NCT02996266
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers